Eikon Holds $596M Cash, Boosts R&D 24% on Oncology Pipeline
Eikon ended Q1 2026 with $596 million cash, funding operations into H2 2027, and R&D expenses climbed 24% to $70 million, including a $5 million milestone payment. Three lead oncology programs—EIK1001, EIK1003 and EIK1005—advanced into Phase2/3 trials with six ASCO abstracts accepted in NSCLC, melanoma, ovarian and breast cancer.
1. Q1 Financial Results
Eikon ended Q1 2026 with $596 million in cash, cash equivalents and marketable securities, providing runway into the second half of 2027. R&D expenses rose 24% year-over-year to $70 million, driven by clinical trial acceleration and a $5 million milestone payment; G&A expenses were $17.3 million.
2. Clinical Pipeline Updates
The company continues to advance three lead oncology programs: EIK1001—dual TLR7/8 agonist—in Phase 2/3 trials with fully enrolled NSCLC cohorts; EIK1003—selective PARP1 inhibitor—completed dose escalation and initiated a Phase 2 dose optimization; EIK1005—WRN helicase inhibitor—began Phase 1/2 dosing in February 2026.
3. Upcoming Milestones
Six abstracts from these programs have been accepted for presentation at the ASCO annual meeting, covering safety, tolerability, efficacy and pharmacokinetic data. CEO Roger Perlmutter will present clinical progress at the Bank of America Securities Global Healthcare Conference on May 12, 2026.